Today we welcome our new CEO, Ricardo Perdigão Henriques. Ricardo has a PhD in Molecular Biology and is a Harvard/MIT-educated scientist. He is also experienced in Venture Capital, Drug Development, Licensing, Business Development and Market Analysis.
Ricardo was in the past a Senior International Business Analyst at BIAL and prior to that, a Life Sciences Investment Manager at Portugal Ventures - the largest Venture Capital firm in Portugal - where he was a Board Member at six portfolio Biotech companies.
Worldwide, there are several unmet medical needs for which new disease-modifying treatments are desperately needed. To address this global need, and capitalizing on Hovione Capital’s shareholders’ experience, who have successfully built a 60-year-old sustainable multi-million dollar business in the pharmaceutical industry, Hovione Capital will start from now on also investing in projects within the Therapeutics’ field and help bring new drugs to patients in need. Besides Therapeutics, Hovione Capital will also keep investing in disruptive technology in the MedTech and Digital Health sectors.
Best wishes for Ricardo, may he have a long and productive journey with us!